4.7 Article

Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease

Journal

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jamda.2016.03.020

Keywords

Body composition; sarcopenic obesity; chronic obstructive pulmonary disease; 6-minute walking distance; fibrinogen; systemic inflammation

Funding

  1. American Board of Internal Medicine
  2. Advantage Healthcare
  3. Almirall
  4. American Thoracic Society
  5. AstraZeneca
  6. Baxter
  7. Boehringer Ingelheim
  8. Chiesi
  9. ClearView Healthcare
  10. Cleveland Clinic
  11. Complete Medical Group
  12. CSL
  13. Dailchi Sankyo
  14. Decision Resources
  15. Forest
  16. Gerson Lehman
  17. Grifols
  18. GroupH
  19. Guidepoint Global
  20. Haymarket
  21. Huron Consulting
  22. Inthought
  23. Johnson and Johnson
  24. Methodist Health System-Dallas
  25. NCI Consulting
  26. Novartis
  27. Pearl
  28. Penn Technology
  29. Pfizer
  30. Merck
  31. GlaxoSmithKline [SCO10490, NCT00292552]
  32. Nycomed
  33. ECLIPSE
  34. Takeda
  35. European Respiratory Society [STRTF 2013-2399]
  36. Planning-Shop
  37. PSL FirstWord
  38. Qwessential
  39. WebMD

Ask authors/readers for more resources

Background: Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective: To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants: Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements: All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results: Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0-5.4, P <.001). In patients with COPD, SO was related to reduced 6-minute walking distance (-28.0 m, 95% CI -45.6 to -10.4), P <.01) and to higher systemic inflammatory burden (an elevation of at least 2 inflammatory markers, OR 1.6, 95% CI 1.1-2.5, P =.028) compared with the normal body composition group after adjustments for age, sex, smoking, body mass index, and airflow limitation. Conclusions: Our findings suggest that SO is associated with worse physical performance and higher systemic inflammatory burden compared with other body composition phenotypes in patients with COPD. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available